ACTU vs LDOS · $49.0M cap vs P/E 16, rev $8.96B
Actuate Therapeutics, Inc. Common stock (ACTU) versus Leidos Holdings Inc (LDOS) — a side-by-side from cached financials, not a winner call.
Actuate Therapeutics, Inc. Common stock (ACTU) is a biotechnology company listed on NASDAQ.
Leidos Holdings Inc (LDOS) is a information technology services company listed on US.
ACTU does not have a complete income-statement cache yet.
Latest reported LDOS revenue for 2026-07-03 was $8.96B. Net income was $682.0M. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
ACTU currently screens at market cap $49.0M. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
Not investment advice. Open the ACTU and LDOS stock pages for the full models.
Not investment advice.